B-cell non-Hodgkin lymphomas

Clinical trials for B-cell non-Hodgkin lymphomas explained in plain language.

Never miss a new study

Get alerted when new B-cell non-Hodgkin lymphomas trials appear

Sign up with your email to follow new studies for B-cell non-Hodgkin lymphomas, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

New drug ATG-031 targets Hard-to-Treat cancers in first human trial

Disease control Stopped early

This study tests an experimental drug called ATG-031 in people with advanced solid tumors or B-cell non-Hodgkin lymphomas that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Participants receive ATG-031 by infusion…

Matched conditions: B-CELL NON-HODGKIN LYMPHOMAS

Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control

Last updated Jul 18, 2026 00:00 UTC

B-cell non-Hodgkin lymphomas

Get alerted when new B-cell non-Hodgkin lymphomas trials appear

New drug ATG-031 targets Hard-to-Treat cancers in first human trial